Biomedical Engineering
BioMimetic Therapeutics, Inc. Announces Pricing of Public Offering
Published in Drug Law Weekly, March 6th, 2007
BioMimetic Therapeutics, Inc. (Nasdaq: BMTI) announced the pricing of an offering of 2,829,000 shares of its common stock at a price of $17.15 per share. Of the shares of common stock being offered, 2,123,575 are being offered by the Company, with the remaining 705,425 shares of common stock being sold by selling stockholders identified in the prospectus. BioMimetic Therapeutics, Inc. will not receive any proceeds from the sale by the selling stockholders.
BioMimetic and one of the selling stockholders have granted the underwriters a 30-day option to purchase an additional 393,536 shares and 30,814 shares, respectively, of common stock to cover over-allotments, if any....
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
Source: Drug Law Weekly (2007-03-06)
More Articles from Drug Law Weekly
- Acute Myelogenous Leukemia
Vion Pharmaceuticals Enters into an Agreement to Sell Convertible Senior Notes and Warrants - Antisense Technology
Genta Incorporated Announces Fourth Quarter and Year End 2006 Financial Results and Corporate Highlights - Biomedical Engineering
BioMimetic Therapeutics, Inc. Completes Public Offering of Approximately 3.25 Million Shares of Common Stock Including the Sale of All Over-Allotment Shares - Breast Cancer
Philadelphia Hormone Therapy Trial Completed - Cancer
Advanced Magnetics Announces Settlement of Lawsuit with Cytogen Corporation - Cytogen Corporation
Cytogen Announces Settlement Agreement with Advanced Magnetics - More from this issue of Drug Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
